Laura A. VanBlargan

Nov 30, 2023 | cell.com | Lucas Adams |Laura A. VanBlargan |Rita E. Chen |Bradley Whitener

Highlights•NTD mAbs block SARS-CoV-2 infection at a post-attachment step•SARS2-57 mAb recognizes most variants and confers Fc-mediated protection in mice•Cryo-EM reveals SARS2-57 binds loops N3 and N5 of the NTD supersite•Cryo-EM reveals the basis of SARS2-57 variant recognition and immune evasionSummaryMost neutralizing anti-SARS-CoV-2 monoclonal antibodies (mAbs) target the receptor binding domain (RBD) of the spike (S) protein.